Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.

Glazer J, Huskamp HA, McGuire TG.

Forum Health Econ Policy. 2012 Mar 30;15(2). pii: 1558-9544.1296.

PMID:
23372543
[PubMed]
Free PMC Article
2.

The effect of a three-tier formulary on antidepressant utilization and expenditures.

Hodgkin D, Parks Thomas C, Simoni-Wastila L, Ritter GA, Lee S.

J Ment Health Policy Econ. 2008 Jun;11(2):67-77.

PMID:
18509214
[PubMed - indexed for MEDLINE]
3.

Formulary management in the Department of Defense.

Trice S, Devine J, Mistry H, Moore E, Linton A.

J Manag Care Pharm. 2009 Mar;15(2):133-46.

PMID:
19236127
[PubMed - indexed for MEDLINE]
Free Article
4.

Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.

Cecil WT, Barnes J, Shea T, Coulter SL.

J Manag Care Pharm. 2006 Oct;12(8):665-76.

PMID:
17269845
[PubMed - indexed for MEDLINE]
Free Article
5.

Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.

Brill JV.

Am J Health Syst Pharm. 2007 Aug 1;64(15 Suppl 10):S3-6; quiz S21-S23. Review.

PMID:
17646551
[PubMed - indexed for MEDLINE]
6.

Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Lipsy RJ.

Pharmacoeconomics. 1992 Apr;1(4):265-81.

PMID:
10147017
[PubMed - indexed for MEDLINE]
7.

Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states.

Khan S, Sylvester R, Scott D, Pitts B.

J Manag Care Pharm. 2008 Oct;14(8):780-9.

PMID:
18983207
[PubMed - indexed for MEDLINE]
Free Article
8.

The effect of incentive-based formularies on prescription-drug utilization and spending.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.

N Engl J Med. 2003 Dec 4;349(23):2224-32.

PMID:
14657430
[PubMed - indexed for MEDLINE]
Free Article
9.

Perverse incentives in the Medicare prescription drug benefit.

McAdams D, Schwarz M.

Inquiry. 2007 Summer;44(2):157-66.

PMID:
17850042
[PubMed - indexed for MEDLINE]
10.

The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees.

Huskamp HA, Deverka PA, Landrum MB, Epstein RS, McGuigan KA.

Health Serv Res. 2007 Oct;42(5):1926-42.

PMID:
17850526
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.

Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS.

Am J Manag Care. 2004 Mar;10(3):201-8.

PMID:
15032257
[PubMed - indexed for MEDLINE]
Free Article
12.

Predictors of satisfaction of health plan members with prescription drug benefits.

Motheral BR, Heinle SM.

Am J Health Syst Pharm. 2004 May 15;61(10):1007-14.

PMID:
15160776
[PubMed - indexed for MEDLINE]
13.

Incentive formularies and changes in prescription drug spending.

Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, Newhouse JP.

Am J Manag Care. 2007 Jun;13(6 Pt 2):360-9.

PMID:
17567237
[PubMed - indexed for MEDLINE]
Free Article
14.

Family income and the impact of a children's health insurance program on reported need for health services and unmet health need.

Feinberg E, Swartz K, Zaslavsky A, Gardner J, Walker DK.

Pediatrics. 2002 Feb;109(2):E29.

PMID:
11826239
[PubMed - indexed for MEDLINE]
15.

The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?

Huskamp HA, Epstein AM, Blumenthal D.

Health Aff (Millwood). 2003 May-Jun;22(3):149-58.

PMID:
12757279
[PubMed - indexed for MEDLINE]
Free Article
16.

Formularies, therapeutics, and outcomes: new opportunities.

Fullerton DS, Atherly DS.

Med Care. 2004 Apr;42(4 Suppl):III39-44.

PMID:
15026670
[PubMed - indexed for MEDLINE]
17.

Savings needed to fund health insurance and health care expenses in retirement: findings from a simulation model.

Fronstin P, Salisbury D, VanDerhei J.

EBRI Issue Brief. 2008 May;(317):1-2, 4-27.

PMID:
18630312
[PubMed - indexed for MEDLINE]
18.

Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states.

Nair KV, Ganther JM, Valuck RJ, McCollum MM, Lewis SJ.

J Manag Care Pharm. 2002 Nov-Dec;8(6):477-91.

PMID:
14613381
[PubMed]
Free Article
19.

Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.

Panzer PE, Regan TS, Chiao E, Sarnes MW.

Am J Manag Care. 2005 Oct;11(12 Suppl):S370-9.

PMID:
16236019
[PubMed - indexed for MEDLINE]
Free Article
20.

PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.

Cline RR, Worley MM, Schondelmeyer SW, Schommer JC, Larson TA, Uden DL, Hadsall RS.

Res Social Adm Pharm. 2010 Jun;6(2):130-42. doi: 10.1016/j.sapharm.2010.04.002.

PMID:
20511112
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk